uMotif and Xperiome Rare Disease Recruitment Collaboration
uMotif has announced its collaboration with Xperiome to bring value to both life science companies conducting clinical trials and the patients participating in them, offering an approach to patient recruitment through a community of patients and an engagement platform to drive retention.
Specifically, the partnership will leverage Xperiome’s knowledge of rare disease to build an understanding of hard-to-reach populations. Xperiome combines these insights with a specialized matching engine, to connect research-ready members to clinical and real-world study opportunities. Then, once enrolled, uMotif’s patient-engagement app will capture large volumes of ePRO, eDiary and symptom data in real-time throughout the duration of a clinical study. The uMotif app empowers patients to manage and collect their own data.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
